Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : CELSION CORP. (CLN was CELN) UP $.33 TO $.59 ON HUGE NEWS -- Ignore unavailable to you. Want to Upgrade?

To: Dave Gore who wrote (251)	1/31/1999 4:57:00 PM
From: Larry Brew	Read Replies (1) \| Respond to of 518

All, One more hour and the big money will be on the line! Broncos and Falcons. Makes Celn a peanut game. <gg> Larry

To: Dave Gore who wrote (251)	1/31/1999 5:51:00 PM
From: Tech Master	Respond to of 518

1) Look here for CELN's capital structure and profile: biz.yahoo.com 2) Insider buying recently: biz.yahoo.com Recent sellers were outsiders (October) the rest are management and directors buying. 3) Recent financing was all Rule 144 common stock under a 506 filing. There are no floorless convertible deals or any of that garbage... Volk is way too smart for that kind of nonsense. Other director info from CELN web site: We have appointed Dr. Max Link former Chairman of (1) Sandoz Pharma AG, (from 1991 to 1993) and (2) Corange Ltd., (1993-1994) as a new director. Corange was recently purchased by Hoffman-LaRoche for $11.5 billion. At present, Dr. Link serves on the Boards of Human Genome Sciences, Alexion Pharmaceuticals, Cell Therapeutics, Access Pharmaceuticals, Protein Design Laboratories and Osiris Therapeutics. His world-wide breadth of experience in bio-technology will be invaluable as we expand into targeted drug delivery and gene therapy. We have also appointed Walter Herbst, Chairman and principal of Herbst LaZar Bell, a designing and engineering company in Chicago, as a new director of the company.

To: Dave Gore who wrote (251)	1/31/1999 6:09:00 PM
From: Tech Master	Read Replies (1) \| Respond to of 518

ADVISOR POSITION & RELATIONSHIP TO CELSION Dr. Augustine Cheung, PhD Chairman & Chief Scientific Officer, Celsion Expertise: Microwave Thermotherapy Technology Dr. Gerald Wolf, MD, PhD Director, Center for Imaging & Pharmaceutical Research, Massachusetts General Hospital Expertise: Focused Heat Energy for Tumor Ablation Dr. Gloria Li, PhD Director, Radiation Biology Laboratory, Memorial Sloan-Kettering Hospital Expertise: Heat Shock and Gene Therapy Dr. Arnold Melman, MD Chairman, Department of Urology, Albert Einstein College of Medicine Expertise: Clinical Studies, Urology Dr. Mark Dewhirst, DVM, PhD Professor of Radiology & Oncology, Duke University Expertise: Temperature Sensitive Liposomes / Thermotherapy Dr. David Neeham, PhD Associate Professor, Dept. of Material Science, Duke University Expertise: Temperature Sensitive Liposomes Dr. Michael Davidson, MD President & CEO, Chicago Center for Clinical Research Expertise: Clinical Trials and FDA Approvals Dr. Daniel Kapp, MD, PhD Professor of Radiation Oncology, Stanford University Expertise: Clinical Studies / Thermotherapy Dr. Robert Barnett, MD Former President, American Cancer Society, Maryland Chapter Expertise: Oncological Surgeon Mr. Donald Beard Former Senior Program Manager, US Department of Energy Expertise: Technology and Business Development Dr. Thomas Ripley, PhD Director of Operations, Grace Biomedical, W.R. Grace & Co. Expertise: Technology and Business Development Dr. Mays Swicord, PhD Director of Research, Motorola Corporation Expertise: Biological Effects of Microwaves Dr. Claude Tihon, PhD President and CEO, Conti-Med, Inc. Expertise: Urological Devices, Regulation & Commercialization